Abstract:BACKGROUND Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and obliterative pulmonary vascular remodeling that result in right heart hypertrophy, failure and premature death. One of the hallmarks of PAH is vascular fibrosis, an excessive deposition of extracellular matrix components (most notably collagen) in the vessel wall, which has been shown to have an important role in the pathogenesis of severe vascular remodeling. Our goal is to gain a better understanding of the mechanisms underlying pulmonary vascular fibrosis seen in IPAH patients in order to identify potential new drug target(s) to inhibit pulmonary vascular fibrosis and thereby prevent/reverse vascular remodeling for treatment of PAH. METHODS Employing the mice with Tie2 Cre‐mediated deletion of Egln1 which encodes hypoxia‐inducible factor prolyl hydroxylase 2, PHD2 ( Egln1 Tie2Cre ), and double knockout mice with Tie2 Cre‐mediated genetic deletions of both Egln1 and Hif1a (EH1) or Egln1 and Hif2a (EH2), we studied the role of PHD2 deficiency and HIF activation in inducing pulmonary vascular fibrosis. Trichrome staining was used to quantify pulmonary vascular fibrosis. Quantitative RT‐PCR analysis and immunostaining were carried out to define the molecular mechanisms of vascular fibrosis associated with PAH in Egln1 Tie2Cre mice. RESULTS Similar to IPAH lungs, mice inactivated for PHD2 in endothelial cells exhibited obliterative vascular remodeling with massive collagen deposition in the vessel wall as observed in Figure 1A . There was however no marked increase of interstitial fibrosis in Egln1 Tie2 lungs. Intriguingly, pulmonary vascular fibrosis was inhibited by genetic deletion of HIF2α but not HIF1α, suggesting an important role of activation of HIF2α secondary to PHD2 deficiency in mediating pulmonary vascular fibrosis. Quantitative RT‐PCR analysis revealed a marked increase of fibrotic markers such as collagen 1α1, 1α2 and 3α1 in Egln1 Tie2Cre mouse lungs, which was inhibited in EH2 mouse lungs. Another important feature of vascular fibrosis is the presence of myofibroblasts, which are responsible for extracellular matrix (ECM) production and accumulation. Immunostaining demonstrated prominent expression of periostin, a marker for myofibroblasts in Egln1 Tie2Cre mouse lungs. The number of cells co‐stained with α‐smooth muscle actin and periostin was drastically increased in the vessel wall of Egln1 Tie2 mouse lungs. CONCLUSIONS Our results demonstrate that endothelial PHD2 deficiency and resultant activation of HIF2α are responsible for pulmonary vascular fibrosis in the newly discovered mouse model of PAH with obliterative vascular remodeling and progressive right heart failure. We also showed that in vivo PHD2 deletion increases the number of myofibroblasts in the vessel wall. These studies defined an unexpected role of PHD2 deficiency in the mechanisms of vascular fibrosis associated with severe PAH. Thus, targeting PHD2/HIF‐2α signaling is a promising strategy to reverse vascular fibrosis for treatment of severe PAH and promote survival.

Hif2 Alpha is Required for the Development of Pulmonary Vascular Fibrosis Associated with Pulmonary Arterial Hypertension

Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis

Suppression of Tissue Inhibitors of Metalloproteinases May Reverse Severe Pulmonary Arterial Hypertension.

Abstract 14566: the Role of Eosinophils in Pulmonary Hypertension

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α

Abstract 17370: Activation of Endothelial GCN2 Kinase Contributes to Pulmonary Vascular Remodeling and Pulmonary Arterial Hypertension

PHD2 deletion in endothelial or arterial smooth muscle cells reveals vascular cell type-specific responses in pulmonary hypertension and fibrosis

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Loss of Prolyl Hydroxylase 1 and 2 in SM22α-Expressing Cells Prevents Hypoxia-Induced Pulmonary Hypertension.

Endothelial HIF-2α Contributes to Severe Pulmonary Hypertension Due to Endothelial-to-mesenchymal Transition.

Abstract 14496: HIF2a Activation Reduces Pulmonary Angiogenesis and Promotes Vascular Remodeling in Pulmonary Arterial Hypertension by Suppressing Wnt7a Production in Pulmonary Endothelial Cells

The Effect of HIF Inhibition on the Phenotype of Fibroblasts in Human and Bovine Pulmonary Hypertension

Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension

Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension

Endothelial HIFα/PDGF-B to smooth muscle Beclin1 signaling sustains pathological muscularization in pulmonary hypertension

Hypoxia-inducible factor signaling in pulmonary hypertension.

Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

Dual PEDF and HGF Overexpression: A New Therapy for Pulmonary Hypertension

Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach

General Capillary Endothelial Cells Undergo Reprogramming into Arterial Endothelial Cells in Pulmonary Hypertension through HIF-2α/Notch4 Pathway